company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3213353.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3213353.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,83539.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,83539.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3129814.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3357486.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11924406.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15281892.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12152078.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12152078.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1155.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12150923.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12150923.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12150923.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,91766799.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,91766799.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:25:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3396507.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3396507.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7214.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7214.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3389293.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3374069.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12448865.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15822934.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12433641.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12433641.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,24065.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12409576.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12409576.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12409576.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,93626893.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,93626893.0
Halozyme Therapeutics Inc,HALO,,0001159036,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:29:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7543894.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7543894.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7532177.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3405966.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13785797.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17191763.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9659586.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-23869.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,23869.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9635717.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,96400000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,96400000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96400000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 16:59:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23188948.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23188948.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,178235.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,178235.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23010713.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4567666.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15347116.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19914782.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3095931.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-20357.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,20357.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3116288.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3116288.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3116288.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3116288.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,102671410.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,104393835.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,103900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 09:02:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22942428.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22942428.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11723.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11723.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22930705.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4263520.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13514352.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17777872.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5152833.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5152833.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,12360.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5165193.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5165193.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5165193.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,103223352.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,105009189.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,103300000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2411166.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2411166.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,56159.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,56159.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2355007.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5866921.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14916205.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20783126.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18428119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,44226.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,69090.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,24864.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18403255.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-12360.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18415615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18415615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18415615.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,104100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,104100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,102566089.0
Halozyme Therapeutics Inc,HALO,,0001159036,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7440179.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7440179.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,70761.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,70761.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7369418.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6618707.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15891109.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22509816.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15140398.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15140398.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,21217.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15119181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15119181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15119181.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,108000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,108000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,107589514.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 17:27:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7757175.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7757175.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,143120.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,143120.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7614055.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5580424.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16081729.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21662153.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14048098.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14048098.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,26979.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14021119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14021119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14021119.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,107900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,107900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112063665.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q2,2012-04-01,2012-06-30,2013-08-07 17:07:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5334323.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5334323.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,226635.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,226635.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5107688.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5634034.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19503491.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25137525.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20029837.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20029837.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,23991.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20005846.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20005846.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20005846.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,111100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,111100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112305002.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 16:32:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21793323.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21793323.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,653484.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,653484.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21139839.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6978835.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18567671.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25546506.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4406667.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,73000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,73000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4333667.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-72187.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4405854.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4405854.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4405854.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,111600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,111600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,111077000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11834000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11834000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,739000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,739000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11095000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7556000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22034000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29590000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18495000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,848000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-848000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19343000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,55000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19288000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19288000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19288000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,113500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,113500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112417000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:36:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14454000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14454000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1284000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1284000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13170000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7300000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27991000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35291000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22121000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,849000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-849000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22970000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,58000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22912000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22912000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22912000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,114600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,114600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112486000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q2,2013-04-01,2013-06-30,2014-08-11 16:29:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16013000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16013000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,683000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,683000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15330000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8135000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25689000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33824000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18494000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19344000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,52000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19292000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,113500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,113500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112765000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:48:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12498000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12498000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3540000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3540000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8958000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9356000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20926000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30282000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21324000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,727000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,229000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-498000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21822000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-165000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,112800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,112800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112805000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11966000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11966000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5520000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5520000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6446000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10250000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21415000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31665000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25219000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26595000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,47000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26548000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26548000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26548000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,120700000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,120700000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118943000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:17:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18385000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18385000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5924000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5924000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8752000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18649000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27401000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14940000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1451000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1451000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16391000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,118000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16273000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16273000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16273000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,123710000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,123710000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125200000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:15:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14606000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14606000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5141000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5141000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9465000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8587000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19904000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28491000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19026000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20402000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,122000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20280000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20280000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20280000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,124041000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,126800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,126800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:10:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30377000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30377000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6147000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6147000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24230000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8353000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19728000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28081000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3851000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1378000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,242000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1136000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4987000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-287000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,122100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,122100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,122690000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18666000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18666000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6494000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6494000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12172000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9399000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16684000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26083000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13911000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1299000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1299000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15210000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,102000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15108000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15108000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15108000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,125299000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,125900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 16:34:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43384000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43384000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8144000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8144000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35240000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9814000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21195000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31009000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4231000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1299000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,87000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1212000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3019000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,126144000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,134507000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,151000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:09:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20780000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20780000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6180000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6180000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10226000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27611000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37837000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23237000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1301000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1301000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,78000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24382000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,126921000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,128700000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,128700000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:08:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,42499000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,42499000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7762000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7762000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,34737000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10806000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50906000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16169000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3876000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,229000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3647000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19816000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127615000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,123900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,123900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:23:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33336000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33336000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8308000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8308000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25028000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11221000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35530000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46751000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21723000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5249000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4852000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26575000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,300000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26875000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26875000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26875000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127958000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,128000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,128000000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:13:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31853000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31853000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9134000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9134000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22719000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33863000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45462000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22743000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5253000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,334000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4919000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27662000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1284000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28946000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-28946000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-28946000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,128154000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,128154000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:14:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,39003000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,39003000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8002000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8002000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31001000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12227000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41349000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53576000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22575000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,366000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5233000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27808000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-422000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27386000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27386000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27386000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127964000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,127964000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,127200000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29568000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29568000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7544000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7544000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22024000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12615000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36935000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49550000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27526000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5448000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,287000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5161000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32687000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,210000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,128615000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,126500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,126500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:37:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33750000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33750000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7788000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7788000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25962000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13101000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38339000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51440000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25478000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5540000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,435000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5105000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30583000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,180000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30763000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30763000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30763000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,134013000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,133800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,133800000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:29:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,63731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,63731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8332000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8332000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,55399000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13329000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33993000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47322000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8077000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5538000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,790000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4748000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3329000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,580000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2749000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2749000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2749000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,141190000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,143236000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,137500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:14:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,189564000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,189564000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7488000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7488000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,182076000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14771000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56147000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,125929000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5458000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1080000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4378000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,121551000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2331000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,123882000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,123882000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,123882000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,136419000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.93
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,139068000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.92
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136900000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.93
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30872000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30872000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3052000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3052000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27820000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13556000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,37976000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51532000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23712000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5230000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1668000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3562000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27274000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,187000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27461000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,142656000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,142656000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,144500000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:08:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35202000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35202000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,836000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,836000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,34366000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14353000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40086000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54439000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20073000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4770000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1983000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2787000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22860000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,33000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22893000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22893000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22893000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,143100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,143568000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:18:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,25556000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,25556000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,626000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,626000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,24930000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14864000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35540000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50404000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25474000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4286000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1910000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2376000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27850000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,146600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,143949000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:21:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,60232000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,60232000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5622000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5622000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,54610000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18031000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36650000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54681000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-71000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3755000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2017000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1738000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1809000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,317000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2126000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2126000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2126000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,143599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,143599000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56949000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56949000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4649000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4649000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,52300000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18006000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,31328000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49334000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2966000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3205000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2057000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1148000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1818000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1796000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1796000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1796000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,179600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,179600000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,144743000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:09:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,39148000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,39148000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1877000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1877000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37271000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17338000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33910000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51248000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13977000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2613000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1983000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-630000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14607000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14624000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14624000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14624000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,146200000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146200000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,145411000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:18:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46230000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46230000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22333000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22333000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23897000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17979000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30455000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48434000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24537000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2078000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1613000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-465000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25002000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25015000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,147100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,147100000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,146136000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:21:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,53665000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,53665000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16687000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16687000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36978000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23929000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,45111000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,69040000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32062000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3731000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1333000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2398000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34460000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-63000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-34397000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,144329000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,144329000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,144329000.0
Halozyme Therapeutics Inc,HALO,,0001159036,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
